Praxis Precision Medicines (PRAX) Cash & Equivalents (2019 - 2026)

Praxis Precision Medicines' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $536.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 223.94% year-over-year to $536.3 million; the TTM figure through Mar 2026 stood at $536.3 million (up 223.94% YoY), while the FY2025 annual figure was $357.3 million, up 65.91% from the prior year.
• Cash & Equivalents was $536.3 million for Q1 2026 at Praxis Precision Medicines, up from $357.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $536.3 million in Q1 2026 to a low of $56.0 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $158.4 million across 5 years, with a median of $145.1 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents plunged 68.14% in 2022, then surged 223.94% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $61.6 million in 2022, then jumped by 31.95% to $81.3 million in 2023, then surged by 164.91% to $215.4 million in 2024, then soared by 65.91% to $357.3 million in 2025, then soared by 50.1% to $536.3 million in 2026.
• The last three Cash & Equivalents figures came in at $536.3 million (Q1 2026), $357.3 million (Q4 2025), and $149.5 million (Q3 2025), per Business Quant data.